Suomi - suomi - Fimea (Suomen lääkevirasto)

stada arzneimittel ag - duloxetine hydrochloride - enterokapseli, kova - 30 mg - duloksetiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

stada arzneimittel ag - duloxetine hydrochloride - enterokapseli, kova - 60 mg - duloksetiini

Euroopan unioni - suomi - EMA (European Medicines Agency)

diurnal europe b.v. - hydrokortisoni - lisämunuaisen vajaatoiminta - kortikosteroidit systeemiseen käyttöön - korvaushoitona lisämunuaisten vajaatoiminnassa imeväisillä, lapsilla ja nuorilla (syntymästä < 18 vuotta vanha).

Euroopan unioni - suomi - EMA (European Medicines Agency)

roche registration limited - emicizumab - hemofilia a - hemostaatit - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra voidaan käyttää kaikissa ikäryhmissä.

Euroopan unioni - suomi - EMA (European Medicines Agency)

novartis europharm limited  - voretigene neparvovec - leber congenital amaurosis; retinitis pigmentosa - other ophthalmologicals - luxturna on tarkoitettu hoito aikuis-ja lapsipotilailla, joilla on näön menetys johtuu perinnöllinen verkkokalvon dystrofia aiheuttama vahvisti biallelic rpe65-mutaatioita ja jotka ovat riittävän kannattavia verkkokalvon soluja.

Suomi - suomi - Fimea (Suomen lääkevirasto)

laboratoire aguettant - suxamethonium chloride anhydrous - injektioneste, liuos, esitäytetty ruisku - 10 mg/ml - suksametoni

Suomi - suomi - Fimea (Suomen lääkevirasto)

ethypharm - suxamethonium chloride - injektio-/infuusioneste, liuos - 50 mg/ml - suksametoni

Suomi - suomi - Fimea (Suomen lääkevirasto)

uni-pharma kleon tsetis pharmaceutical laboratories - thiamazole - tabletti - 5 mg - tiamatsoli

Euroopan unioni - suomi - EMA (European Medicines Agency)

mylan ireland limited - rivaroksabaani - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitromboottiset aineet - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Euroopan unioni - suomi - EMA (European Medicines Agency)

biomarin international limited - valoctocogene roxaparvovec - hemostaatit - treatment of severe haemophilia a (congenital factor viii deficiency) in adult patients without a history of factor viii inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (aav5).